Abstract
Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Keywords: Melatonin, Alzheimer's disease; Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, autism spectrum disorders, attention-deficit hyperactivity disorder, headaches, epilepsy, spinal cord injury, ischemic stroke, sleep disorders.
Current Medicinal Chemistry
Title:Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Volume: 24 Issue: 35
Author(s): Emilio J. Sanchez-Barcelo*, Noemi Rueda, María D. Mediavilla , Carmen Martinez-Cue and Russel J. Reiter
Affiliation:
- Department of Physiology & Pharmacology, School of Medicine, University of Cantabria, 39011 Santander,Spain
Keywords: Melatonin, Alzheimer's disease; Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, autism spectrum disorders, attention-deficit hyperactivity disorder, headaches, epilepsy, spinal cord injury, ischemic stroke, sleep disorders.
Abstract: Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory “bench” are not always applicable to the patient's “bedside”.
Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology.
Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.
Export Options
About this article
Cite this article as:
Sanchez-Barcelo J. Emilio*, Rueda Noemi , Mediavilla D. María , Martinez-Cue Carmen and Reiter J. Russel , Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders, Current Medicinal Chemistry 2017; 24 (35) . https://dx.doi.org/10.2174/0929867324666170718105557
DOI https://dx.doi.org/10.2174/0929867324666170718105557 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanobiotechnological Approaches Against Multidrug Resistant Bacterial Pathogens: An Update
Current Drug Metabolism p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry The Use of Flavonoids in Central Nervous System Disorders
Current Medicinal Chemistry Gastrodia Elata Bl Attenuates Cocaine-Induced Conditioned Place Preference and Convulsion, but not Behavioral Sensitization in Mice: Importance of GABAA Receptors
Current Neuropharmacology The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Purification and Biological Evaluation of Some Bioactive Metabolomics as Antimicrobial Agent
Letters in Drug Design & Discovery PET Radiotracers for Molecular Imaging of Serotonin 5-HT<sub>1A</sub> Receptors
Current Medicinal Chemistry Voltage-Gated Sodium Channels and Pain
Current Drug Targets - CNS & Neurological Disorders Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
Current Pharmaceutical Design Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism The Four Human γ-Aminobutyric Acid (GABA) Transporters: Pharmacological Characterization and Validation of a Highly Efficient Screening Assay
Combinatorial Chemistry & High Throughput Screening PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders 2-Oxo-1,2,3,4-tetrahydropyrimidines Ethyl Esters as Potent β- Glucuronidase Inhibitors: One-pot Synthesis, In vitro and In silico Studies
Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Current Neuropharmacology Enantiopure 1,2,3-Triazolyl-β-amino Acids via Click Cycloaddition Reaction on Racemic Alkynyl Precursors Followed by Separation of Stereoisomers
Current Topics in Medicinal Chemistry Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research